Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: A phase II pilot study

Arthritis Research and Therapy

Volumn 16, Issue 4, 2014, Pages

  Fraticelli, Paolo ^a   Gabrielli, Barbara ^a   Pomponio, Giovanni ^a   Valentini, Gabriele ^b   Bosello, Silvia ^c   Riboldi, Piersandro ^d   Gerosa, Maria ^d   Faggioli, Paola ^e   Giacomelli, Roberto ^f   Del Papa, Nicoletta ^g   Gerli, Roberto ^h   Lunardi, Claudio ⁱ   Bombardieri, Stefano ^j   Malorni, Walter ^k   Corvetta, Angelo ^l   Moroncini, Gianluca ^m   Gabrielli, Armando ^m  

^a OSPEDALI RIUNITI   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c CATHOLIC UNIVERSITY   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e Internal Medicine   (Italy)

^f UNIVERSITY OF L'AQUILA   (Italy)

^g ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

^h UNIVERSITY OF PERUGIA   (Italy)

ⁱ UNIVERSITY OF VERONA   (Italy)

^j UNIVERSITY OF PISA   (Italy)

^k ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^l OSPEDALE DEGLI INFERMI   (Italy)

^m UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBON MONOXIDE; COLCHICINE; CREATINE KINASE; CYCLOPHOSPHAMIDE; IMATINIB; STEROID;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; ARTHRITIS; ARTICLE; BRAIN; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CHONDROCALCINOSIS; CLINICAL ARTICLE; COUGHING; CREATINE KINASE BLOOD LEVEL; DEATH; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; FORCED VITAL CAPACITY; HIGH RESOLUTION COMPUTER TOMOGRAPHY; HISTOPATHOLOGY; HUMAN; INFECTION; INTERSTITIAL LUNG DISEASE; LOW DRUG DOSE; LUNG DIFFUSION CAPACITY; LUNG FIBROSIS; LUNG FUNCTION; MALABSORPTION; MALE; MALNUTRITION; MENINX; MORNING DOSAGE; MULTICENTER STUDY; NEUROENDOCRINE TUMOR; NONINVASIVE VENTILATION; OPEN STUDY; OUTCOME ASSESSMENT; OXYGEN TENSION; PELVIS; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PNEUMONIA; PNEUMOTHORAX; PRIMARY TUMOR; PROSPECTIVE STUDY; RESPIRATORY FAILURE; SINGLE DRUG DOSE; SKULL; STEROID THERAPY; SUDDEN DEATH; SYSTEMIC SCLEROSIS; THROMBOPHLEBITIS; TREATMENT RESPONSE; TUMOR LOCALIZATION; UNSPECIFIED SIDE EFFECT; URTICARIA; WEAKNESS;

EID: 85028112070     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4606     Document Type: Article

References (34)

1. Gabrielli A, Avvedimento EV, Krieg T. Scleroderma. N Engl J Med 2009, 360:1989-2003.
2. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007, 66:940-944.
3. White B. Interstitial lung disease in scleroderma. Rheum Dis Clin North Am 2003, 29:371-390.
4. Ferri C, Valentini G, Cozzi F, Sebastiani M, Michelassi C, La Montagna G, Bullo A, Cazzato M, Tirri E, Storino F, Giuggioli D, Cuomo G, Rosada M, Bombardieri S, Todesco S, Tirri G, . Systemic Sclerosis Study Group of the Italian Society of Rheumatology (SIR-GSSSc) Systemic sclerosis: demographic, clinical and serological features and survival in 1,012 Italian patients. Medicine (Baltimore) 2002, 81:139-153. Systemic Sclerosis Study Group of the Italian Society of Rheumatology (SIR-GSSSc).
5. Benan M, Hande I, Ongen G. The natural course of progressive systemic sclerosis patients with interstitial lung involvement. Clin Rheumatol 2007, 26:349-354.
6. Schurawitzki H, Stiglbauer R, Graninger W, Herold C, Po¨lzleitner D, Burghuber OC, Tscholakoff D. Interstitial lung disease in progressive systemic sclerosis: high resolution CT versus radiography. Radiology 1990, 176:755-759.
7. Capdeville R, Buchdunger E, Zimmeermann J, Matter A. Glivec (STI571, Imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 2002, 1:493-502.
8. Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH, Leof EB. Imatinib mesylate inhibits the pro-fibrogenic activity of TGF-β and prevents bleomycin mediated lung fibrosis. J Clin Invest 2004, 114:1308-1316.
9. Carrol M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB, Gilliland DG, Druker BJ. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 1997, 90:4947-4952.
10. Pope J, McBain D, Petrlich L, Watson S, Vanderhoek L, de Leon F, Seney S, Summers K. Imatinib in active diffuse cutaneous systemic sclerosis: results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center. Arthritis Rheum 2011, 63:3547-3551.
11. Spiera RF, Gordon JK, Mersten JN, Magro CM, Mehta M, Wildman HF, kloiber S, Kirou KA, Lyman S, Crow MK. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis 2011, 70:1003-1009.
12. Khanna D, Saggar R, Mayes MD, Abtin F, Clements PJ, Maranian P, Assassi S, Saggar R, Singh RR, Furst DE. A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease. Arthritis Rheum 2011, 63:3540-3546.
13. Distler O, Distler JHW, Varga J, Denton CP, Lafyatis RA, Wigley FM, Schett G. A multi-center, open-label, proof of concept study of imatinib mesylate demonstrate no benefit for the treatment of fibrosis in patients with early, diffuse systemic sclerosis. [abstract]. Arthritis Rheum 2010, 62:560.
14. Guo L, Chen XX, Gu YY, Zou HJ, Ye S. Low-dose imatinib in the treatment of severe systemic sclerosis: a case series of six Chinese patients and literature review. Clin Rheumatol 2012, 31:1395-1400.
15. Prey S, Ezzedine K, Doussau A, Grandoulier AS, Barcat D, Chatelus E, Diot E, Durant C, Havchulla E, de Korwin-Krokowski JD, Kostrzewa E, Quemeneur T, Paul C, Schaeverbeke T, seneschal J, Solanilla A, Sparsa A, Bouchet S, Lepreux S, Mahon FX, Chene G, Tai¨eb A. Imatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trial. Br J Dermatol 2012, 167:1138-1144.
16. Simon R, Wittes RE, Ellenberg SS. Randomized phase II clinical trials. Cancer Treat Rep 1985, 69:1375-1381.
17. Simon R. Optimal two stage designs for phase II clinical trials. Control Clin Trials 1989, 10:1-10.
18. Subcommitte for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Commitee Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthrtis Rheum 1980, 23:581-590. Subcommitte for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Commitee.
19. Mahler DA, Weinberg DHW, Wells CK, Feinstein AR. The measurement of dyspnea: contents, inter-observer agreement, and physiologic correlates of two new clinical indexes. Chest 1984, 85:751-758.
20. Wanger J, Clausen JL, Coates A. Standardisation of the measurement of lung volumes. Eur Respir J 2005, 26:511-522.
21. Macintyre N, Crapo RO, Viegi G, Johnson DC, van der Grinten CP, Brusasco V, Burgos F, Casaburi R, Coates A, Enright P, Gustafsson P, Hankinson J, Jensen R, McKay R, Miller MR, Navajas D, Pedersen OF, Pellegrino R, Wanger J. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 2005, 26:720-735.
22. Launay D, Remy-Jardin M, Micron-Pasturel U. High resolution computer tomography in fibrosing alveolitis associated with systemic sclerosis. J Rheum 2006, 33:1789-1801.
23. Clements P, Lachenbruch P, Siebold J, White B, Weiner S, Martin R, Weinstein A, Weisman M, Mayes M, Collier D, Wigley F, Medsger JT, Steen V, Moreland L, Dixon M, Massa M, Lally E, McCloskey D, Varga J, et al. Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995, 22:1281-1285.
24. Khanna D, Clements PJ, Furst DE, Chon Y, Elashoff R, Roth MD, Sterz MG, Chung J, Fitzgerald JD, Seibold JR, Varga J, Theodore A, Wigley FM, Silver RM, Steen VD, Mayes MD, Connolly MK, Fessler BJ, Rothfiels NF, Mubarak K, Molitor J, Tashkin DP, . Scleroderma Lung Study Group Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity of carbon monoxide in patients with systemic sclerosis and active alveolitis. Arthritis Rheum 2005, 52:592-600. Scleroderma Lung Study Group.
25. Guidance for Industry. E6 Good Clinical Practice: Consolidated Guidance. [http://www.fda.gov/downloads/Drugs/Guidances/ucm073122.pdf].
26. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, Arriola E, Silver R, Strange C, Bolster M, Seibold JR, Riley DJ, Hsu VM, Varga J, Schraufnagel DE, Theodore A, Simms R, Wise R, Wigley F, White B, Steen V, Read C, Mayes M, Parsley E, Mubarak K, Connolly MK, Golden J, Olman M, Fessler B, Rothfield N, Metersky M, . Scleroderma Lung Study Research Group Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006, 354:2655-2666. Scleroderma Lung Study Research Group.
27. Maurer B, Distler A, Dees C, Khan K, Denton CP, Abraham D, Gay RE, Michel BA, Gay S, Distler J, Distler O. Levels of target activation predict antifibrotic responses to tyrosine kinase inhibitors. Ann Rheum Dis 2013, 72:2039-2046.
28. Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB, Gilliand DG, Druker BJ. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood 1997, 15:4947-4952.
29. Dewar AL, Cambareri AC, Zannettino AC, Miller BL, Doherty KV, Hughes TP, Lyons AB. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood 2005, 105:3127-3132.
30. Lore´ K, Greiner E, Magnusson MK, Price DA, Douek DC, Dumbar CE. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood 2005, 105:2473-2479.
31. Wallace E, Gewin L. Imatinib: novel treatment of immune-mediated kidney injury. J Am Soc Nephrol 2013, 24:694-701.
32. Crespo O, Kang SC, Daneman R, Lindstrom TM, Ho PP, Sobel RA, Steinman L, Robinson WH. Tyrosine kinase inhibitors ameliorate autoimmune encephalomyelitis in a mouse model of multiple sclerosis. J Clin Immunol 2011, 31:1010-1020.
33. Paniagua RT, Sharpe O, Ho PP, Chan SM, Chang A, Higgins JP, Tomooka BH, Thomas FM, Song JJ, Goodman SB, Lee DM, Genovese MC, Utz PJ, Steinman L, Robinson WH. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J Clin Invest 2006, 116:2633-2642.
34. Louvet C, Szot GL, Lang J, Lee MR, Martinier N, Bollag G, Zhu S, Weiss A, Bluestone JA. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. Proc Natl Acad Sci U S A 2008, 105:18895-18900.